{"analyses":[{"ciLowerLimit":"0.6382","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.4874","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Slope","paramValue":"1.0628","statisticalComment":"degrees of freedom: 4507","statisticalMethod":"ANOVA","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.7","value":"2.6"},{"groupId":"OG001","spread":"3.3","value":"4.8"}]}]}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"1103"},{"groupId":"OG001","value":"320"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"4614"},{"groupId":"OG001","value":"1316"}],"units":"cycles"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.","dispersionType":"Standard Deviation","groups":[{"description":"Cancer patients with solid tumor treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006: Solid Tumor"},{"description":"Cancer patients with hematological tumor treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG001","title":"EP2006: Hematological Tumor"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"EP2006 Day of Initiation by Tumor Type (Solid Tumor vs. Hematological Tumor): Cycle Level","type":"PRIMARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"days"}